查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1618288

抗真菌药物的全球市场的评估:各类药物，各适应症，各给药途径，药物，各类型，各流通管道，各地区，机会，预测(2018年～2032年)

Antifungal Drugs Market Assessment, By Drug Class, By Indication, By Route of Administration, By Medication, By Type, By Distribution Channel, By Region, Opportunities and Forecast, 2018-2032F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 227 Pages | 商品交期: 3-5个工作天内

价格

全球抗真菌药物市场规模预计将从 2024 年的 167.2 亿美元增至 2032 年的 229.7 亿美元，预计 2025-2032 年的复合年增长率为 4.05%。该市场的成长是由皮癣菌病、曲霉菌病、念珠菌病和毛霉菌病患者数量的增加、各监管机构产品批准的增加以及主要製药公司推出新产品的投资增加所推动的。对真菌感染的认识不断提高以及及时干预的重要性也推动了市场需求。世界各地的各个卫生机构和政府正在进行公众宣传活动，以提高公众对真菌感染相关体征、症状和风险的认识，实现早期发现并促进快速治疗的采用。例如，疾病管制中心 (CDC) 及其世界各地的合作伙伴在 2024 年 9 月 16 日至 20 日的真菌疾病意识週 (FDAW) 期间合作提高对真菌疾病的认识。

此外，分子诊断、PCR检测、快速抗原检测等先进诊断工具和技术的开发和引进，提高了真菌感染诊断的准确性和速度，可以进行早期干预。此外，製药公司越来越注重开发和引入治疗解决方案，以解决现有治疗的局限性并改善患者的治疗效果。这些措施包括开发基于奈米技术的製剂，旨在改善临床结果。持续的研究和开发活动促使新的抗真菌药物和製剂的推出。这些进步将提高患者的依从性和治疗效果，特别是解决多重抗药性真菌带来的课题。

此外，医院感染的增加也支持了全球抗真菌药物市场的成长。 CDC 估计，美国每 31 名住院患者中就有 1 人患有至少一种医院相关感染。真菌病原体可以侵入患者的身体并导致健康问题，从危及生命的全身性疾病到轻微的皮肤感染。在医院环境中，真菌病原体通常会透过手术部位、伤口、烧伤和割伤进入体内。

本报告提供全球抗真菌药物市场相关调查分析，提供市场规模与预测，市场动态，主要企业的形势等资讯。

目录

第1章 计划的范围和定义

第2章 调查手法

第3章 摘要整理

第4章 全球抗真菌药物市场预测(2018年～2032年)

  • 市场规模的分析与预测
    • 金额
  • 市场占有率的分析与预测
    • 各类药物
    • 各适应症
    • 各给药途径
    • 各药物
    • 各类型
    • 各流通管道
    • 各地区
    • 市场占有率分析:各企业(金额)(前五名公司和其他 - 2024年)
  • 市场地图分析(2024年)
    • 各类药物
    • 各适应症
    • 各给药途径
    • 各药物
    • 各类型
    • 各流通管道
    • 各地区

第5章 北美的抗真菌药物市场预测(2018年～2032年)

  • 市场规模的分析与预测
    • 金额
  • 市场占有率的分析与预测
    • 各类药物
    • 各适应症
    • 各给药途径
    • 各药物
    • 各类型
    • 各流通管道
    • 占有率:各国
  • 各国的市场评估
    • 美国的抗真菌药物市场预测(2018年～2032年)
    • 加拿大
    • 墨西哥

第6章 欧洲的抗真菌药物市场预测(2018年～2032年)

  • 德国
  • 法国
  • 义大利
  • 英国
  • 俄罗斯
  • 荷兰
  • 西班牙
  • 波兰

第7章 亚太地区的抗真菌药物市场预测(2018年～2032年)

  • 印度
  • 中国
  • 日本
  • 澳洲
  • 越南
  • 韩国
  • 印尼
  • 菲律宾

第8章 南美的抗真菌药物市场预测(2018年～2032年)

  • 巴西
  • 阿根廷

第9章 中东·非洲的抗真菌药物市场预测(2018年～2032年)

  • 沙乌地阿拉伯
  • 阿拉伯联合大公国
  • 南非
  • 以色列

第10章 供需分析

第11章 价值链分析

第12章 波特的五力分析

第13章 大环境分析

第14章 价格分析

第15章 市场动态

  • 推动市场要素
  • 市场课题

第16章 市场趋势与发展

第17章 法规结构和革新

  • 临床试验
  • 法规当局的认证

第18章 专利形势

第19章 案例研究

第20章 竞争情形

  • 前五名市场领导者的竞争矩阵
  • 前五名公司的SWOT分析
  • 前十大主要企业的形势
    • GlaxoSmithKline plc
    • Merck & Co., Inc.
    • Bayer AG
    • Pfizer Inc.
    • Astellas Pharma Inc.
    • Abbott Laboratories
    • Novartis AG
    • Glenmark Pharmaceuticals Limited
    • Enzon Pharmaceuticals, Inc.
    • Sanofi S.A.

第21章 策略性推荐

第22章 本公司相关资料，免责声明

Product Code: MX12438

Global antifungal drugs market is projected to witness a CAGR of 4.05% during the forecast period 2025-2032, growing from USD 16.72 billion in 2024 to USD 22.97 billion in 2032. The market's growth is boosted by the rising cases of dermatophytosis, aspergillosis, candidiasis, and mucormycosis, coupled with increasing product approvals from various regulatory bodies and rising investments by leading pharmaceutical companies toward novel product launches. Growing awareness about fungal infections and the importance of prompt intervention are also bolstering the market's demand. Different healthcare organizations and governments across the globe are increasingly focusing on conducting public awareness campaigns to boost public awareness about the signs, symptoms, and risks associated with fungal infections, allowing for early detection and fostering prompt treatment adoption. For instance, the Centers for Disease Control (CDC) and its partners across the globe worked together to boost awareness about fungal diseases during Fungal Disease Awareness Week (FDAW) from 16-20 September 2024.

Furthermore, the development and incorporation of advanced diagnostic tools and techniques, including molecular diagnostics, PCR tests, and rapid antigen tests, are improving the accuracy and speed of diagnosis of fungal infections, enabling early intervention. Additionally, pharmaceutical companies are increasingly focusing on developing and introducing therapeutic solutions that are able to address the limitations of existing treatments and improve patient outcomes. Such measures include the development of nanotechnology-based formulations designed for improving clinical outcomes. Continuous research and development efforts are leading to the introduction of novel antifungal drugs and formulations. Such advancements enhance patient adherence and treatment efficacy, addressing the challenges posed by multidrug-resistant fungal strains, among others.

Moreover, the rising cases of hospital-acquired infections also support the growth of the global antifungal drugs market. The CDC estimates that 1 in 31 patients hospitalized in the United States suffers from at least one hospital-associated infection. Fungal pathogens can enter the patient's body and can cause health repercussions ranging from systemic diseases that can be life-threatening to mild skin infections. In hospital settings, fungal pathogens usually enter the body through surgical sites, wounds, burns, and cuts.

Increasing Prevalence of Fungal Infections Boosts Market Demand

The rising prevalence of fungal infections in different regions across the globe is one of the major factors supporting the expansion of the antifungal drugs market. According to data published by the International Society for Infectious Diseases (ISID) in September 2024, approximately 6.5 million cases of invasive fungal infections are reported annually. This growing threat of fungal infections is propelling the demand for effective therapeutic solutions and highlighting the importance of increasing understanding and awareness about managing and treating fungal infections to promote patient safety.

The rising number of patient admissions in ICUs also increases the risk of fungal infections in hospital settings. Additionally, the rapid advancements in diagnostics allow the early diagnosis and detection of fungal infections, further augmenting the requirement for antifungal drugs. Additionally, the expansion of the immunocompromised population due to the rise in cases of conditions including HIV/AIDS, diabetes, and cancer is resulting in a higher susceptibility to fungal infections, propelling the requirement for effective medications and therapies.

Rising Investments Toward the Development of Novel Treatments Support Market Expansion

Leading pharmaceutical and biotechnology companies across the globe are actively working on developing and introducing novel therapeutic solutions to treat fungal infections and combat the growing threat of drug-resistant fungal infections. For instance, in September 2024, F2G Ltd announced that they had secured USD 100 million in funding to commercialize their new class of antifungals. With this funding, the company aims to complete the late-stage development of olorofim for invasive aspergillosis and prepare for regulatory approval in the United States. Olorofim, a part of orotomides, a new class of antifungal drugs, inhibits the dihydroorotate dehydrogenase enzyme from disrupting the synthesis of pyrimidines, which is essential for fungi.

Increased investments are also resulting in the development of antifungal resistance networks. In November 2024, the University of Exeter launched an antifungal resistance network worth approximately USD 2.16 million (£1.7 million). Fifteen projects that aim to reduce the growing threat of drug resistance fungal diseases in middle- and low-income countries received funding via the University's FAILSAFE project.

Hospital Pharmacies Account for a Significant Share of the Market

Hospital pharmacies accounted for a significant market share over the historical period and are expected to generate similar results over the forecast period. These pharmacies serve both in- and out-patients, enhancing patient experience and ensuring seamless treatment of fungal infections. The high preference for hospital pharmacies can be attributed to the presence of skilled professionals and pharmacists to guide patients about the potential side effects of the drugs and their appropriate use. Patients also prefer hospitals for receiving treatments for fungal infections due to the comprehensive care available across the healthcare institute, which includes monitoring treatment progress and follow-up consultations, ensuring improved treatment outcomes. Thus, increasing the reliance on hospital pharmacies.

Meanwhile, retail pharmacies are expected to witness significant growth in the coming years. The growth is supported by the convenience provided by these distribution channels because of their personalized services, competitive pricing and discounts, and privacy and discretion. Additionally, these pharmacies also stock OTC and prescription medications, offering a broad range of treatment options and catering to patients suffering from both mild and severe fungal infections.

North America Region Holds Major Market Share

The growth of the North American antifungal drugs market can be attributed to the rising cases of fungal infections in the region, the increase in hospitalization, the strong presence of leading pharmaceutical companies, and growing initiatives by the regional government to bolster public awareness.

Additionally, recent approvals from the regulatory bodies for introducing new antifungal drugs in the region support the market's expansion. In June 2024, Biocon Limited announced that they had secured approval for their complex and integrated injectable product micafungin, available in 100 and 50 mg vials from the United States Food and Drug Administration (US FDA). The drug has been indicated to treat a wide range of yeast and fungal infections. Such approvals are expected to boost the availability of effective treatment solutions in the region, providing lucrative growth opportunities for the market.

Meanwhile, the Asia-Pacific is expected to grow rapidly over the forecast period. This growth is supported by the presence of a large population, increasing investments towards the enhancement of the pharmaceutical and healthcare sectors, and rising prevalence of fungal infections in countries such as Japan.

Future Market Scenario (2025-2032F)

As per the global antifungal drugs market analysis, the market is expected to observe significant growth over the coming years due to the rising cases of fungal infections, growing awareness about the disease among the general population, increasing accessibility of therapies for fungal diseases, and rising investments by leading pharmaceutical companies towards novel product launches. The rapid expansion of the population is also expected to augment the number of cases of fungal diseases, boosting the global antifungal drugs market size. As per the estimates of the United Nations, the global population is projected to reach USD 9.7 billion in 2050.

Additionally, there has been a notable increase in research and development efforts to develop new antifungal agents. Innovations in drug formulations and mechanisms of action are expanding treatment options, particularly for resistant strains of fungi. This continuous pipeline of new products is anticipated to enhance market dynamics significantly.

Increased investments in healthcare infrastructure globally are also expected to facilitate better access to antifungal therapies, further driving market demand. The focus on improving medical facilities will likely lead to more patients seeking treatment for fungal infections.

Key Players Landscape and Outlook

The key players of the market are actively engaging in partnerships to expand their product portfolio and bolster the availability of fungal treatment solutions across different regions, supporting the market's expansion. In March 2023, SCYNEXIS, Inc. and GlaxoSmithKline plc announced an exclusive agreement for commercialization and development of Brexafemme (ibrexafungerp). Brexafemme is used for treating vulvovaginal candidiasis (VVC) and reducing incidences of recurrent VVC. Such activities are expected to augment the availability of antifungal medicines that provide a broad spectrum of activity against both emerging and existing strains of fungi, enhancing patient convenience and expanding the market share of the leading market players.

Additionally, in March 2024, the US FDA granted Astellas Pharma US, Inc.'s CRESEMBA (isavuconazonium sulfate) orphan drug and pediatric exclusivity for treating invasive mucormycosis (IM) and invasive aspergillosis (IA) in pediatric patients. As the first company to receive FDA approval for treating IM and IA in patients that are one year old, Astellas received orphan drug exclusivity, providing them with 7 years of exclusive marketing rights for CRESEMBA.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Antifungal Drugs Market Outlook, 2018-2032F

  • 4.1. Market Size Analysis & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share Analysis & Forecast
    • 4.2.1. By Drug Class
      • 4.2.1.1. Azoles
        • 4.2.1.1.1. Fluconazole
        • 4.2.1.1.2. Voricanazole
        • 4.2.1.1.3. Posaconazole
        • 4.2.1.1.4. Clotrimazole
        • 4.2.1.1.5. Others
      • 4.2.1.2. Polyenes
        • 4.2.1.2.1. Amphotericin B
        • 4.2.1.2.2. Others
      • 4.2.1.3. Allylamines
        • 4.2.1.3.1. Terbinafine
        • 4.2.1.3.2. Naftifine
        • 4.2.1.3.3. Others
      • 4.2.1.4. Echinocandins
      • 4.2.1.5. Others
    • 4.2.2. By Indication
      • 4.2.2.1. Dermatophytosis
      • 4.2.2.2. Aspergillosis
      • 4.2.2.3. Candidiasis
      • 4.2.2.4. Mucormycosis
      • 4.2.2.5. Others
    • 4.2.3. By Route of Administration
      • 4.2.3.1. Oral
      • 4.2.3.2. Topical
      • 4.2.3.3. Injectable
    • 4.2.4. By Medication
      • 4.2.4.1. Prescription
      • 4.2.4.2. OTC
    • 4.2.5. By Type
      • 4.2.5.1. Branded
      • 4.2.5.2. Generic
    • 4.2.6. By Distribution Channel
      • 4.2.6.1. Hospital pharmacies
      • 4.2.6.2. Retail pharmacies
      • 4.2.6.3. Online pharmacies
    • 4.2.7. By Region
      • 4.2.7.1. North America
      • 4.2.7.2. Europe
      • 4.2.7.3. Asia-Pacific
      • 4.2.7.4. South America
      • 4.2.7.5. Middle East and Africa
    • 4.2.8. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
  • 4.3. Market Map Analysis, 2024
    • 4.3.1. By Drug Class
    • 4.3.2. By Indication
    • 4.3.3. By Route of Administration
    • 4.3.4. By Medication
    • 4.3.5. By Type
    • 4.3.6. By Distribution Channel
    • 4.3.7. By Region

5. North America Antifungal Drugs Market Outlook, 2018-2032F*

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Drug Class
      • 5.2.1.1. Azoles
        • 5.2.1.1.1. Fluconazole
        • 5.2.1.1.2. Voricanazole
        • 5.2.1.1.3. Posaconazole
        • 5.2.1.1.4. Clotrimazole
        • 5.2.1.1.5. Others
      • 5.2.1.2. Polyenes
        • 5.2.1.2.1. Amphotericin B
        • 5.2.1.2.2. Others
      • 5.2.1.3. Allylamines
        • 5.2.1.3.1. Terbinafine
        • 5.2.1.3.2. Naftifine
        • 5.2.1.3.3. Others
      • 5.2.1.4. Echinocandins
      • 5.2.1.5. Others
    • 5.2.2. By Indication
      • 5.2.2.1. Dermatophytosis
      • 5.2.2.2. Aspergillosis
      • 5.2.2.3. Candidiasis
      • 5.2.2.4. Mucormycosis
      • 5.2.2.5. Others
    • 5.2.3. By Route of Administration
      • 5.2.3.1. Oral
      • 5.2.3.2. Topical
      • 5.2.3.3. Injectable
    • 5.2.4. By Medication
      • 5.2.4.1. Prescription
      • 5.2.4.2. OTC
    • 5.2.5. By Type
      • 5.2.5.1. Branded
      • 5.2.5.2. Generic
    • 5.2.6. By Distribution Channel
      • 5.2.6.1. Hospital pharmacies
      • 5.2.6.2. Retail pharmacies
      • 5.2.6.3. Online pharmacies
    • 5.2.7. By Country Share
      • 5.2.7.1. United States
      • 5.2.7.2. Canada
      • 5.2.7.3. Mexico
  • 5.3. Country Market Assessment
    • 5.3.1. United States Antifungal Drugs Market Outlook, 2018-2032F*
      • 5.3.1.1. Market Size Analysis & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share Analysis & Forecast
        • 5.3.1.2.1. By Drug Class
          • 5.3.1.2.1.1. Azoles
          • 5.3.1.2.1.1.1. Fluconazole
          • 5.3.1.2.1.1.2. Voricanazole
          • 5.3.1.2.1.1.3. Posaconazole
          • 5.3.1.2.1.1.4. Clotrimazole
          • 5.3.1.2.1.1.5. Others
          • 5.3.1.2.1.2. Polyenes
          • 5.3.1.2.1.2.1. Amphotericin B
          • 5.3.1.2.1.2.2. Others
          • 5.3.1.2.1.3. Allylamines
          • 5.3.1.2.1.3.1. Terbinafine
          • 5.3.1.2.1.3.2. Naftifine
          • 5.3.1.2.1.3.3. Others
          • 5.3.1.2.1.4. Echinocandins
          • 5.3.1.2.1.5. Others
        • 5.3.1.2.2. By Indication
          • 5.3.1.2.2.1. Dermatophytosis
          • 5.3.1.2.2.2. Aspergillosis
          • 5.3.1.2.2.3. Candidiasis
          • 5.3.1.2.2.4. Mucormycosis
          • 5.3.1.2.2.5. Others
        • 5.3.1.2.3. By Route of Administration
          • 5.3.1.2.3.1. Oral
          • 5.3.1.2.3.2. Topical
          • 5.3.1.2.3.3. Injectable
        • 5.3.1.2.4. By Medication
          • 5.3.1.2.4.1. Prescription
          • 5.3.1.2.4.2. OTC
        • 5.3.1.2.5. By Type
          • 5.3.1.2.5.1. Branded
          • 5.3.1.2.5.2. Generic
        • 5.3.1.2.6. By Distribution Channel
          • 5.3.1.2.6.1. Hospital pharmacies
          • 5.3.1.2.6.2. Retail pharmacies
          • 5.3.1.2.6.3. Online pharmacies
    • 5.3.2. Canada
    • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Antifungal Drugs Market Outlook, 2018-2032F

  • 6.1. Germany
  • 6.2. France
  • 6.3. Italy
  • 6.4. United Kingdom
  • 6.5. Russia
  • 6.6. Netherlands
  • 6.7. Spain
  • 6.8. Poland

7. Asia-Pacific Antifungal Drugs Market Outlook, 2018-2032F

  • 7.1. India
  • 7.2. China
  • 7.3. Japan
  • 7.4. Australia
  • 7.5. Vietnam
  • 7.6. South Korea
  • 7.7. Indonesia
  • 7.8. Philippines

8. South America Antifungal Drugs Market Outlook, 2018-2032F

  • 8.1. Brazil
  • 8.2. Argentina

9. Middle East and Africa Antifungal Drugs Market Outlook, 2018-2032F

  • 9.1. Saudi Arabia
  • 9.2. UAE
  • 9.3. South Africa
  • 9.4. Israel

10. Demand Supply Analysis

11. Value Chain Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

  • 15.1. Market Drivers
  • 15.2. Market Challenges

16. Market Trends and Developments

17. Regulatory Framework and Innovation

  • 17.1. Clinical Trials
  • 17.2. Regulatory Approvals

18. Patent Landscape

19. Case Studies

20. Competitive Landscape

  • 20.1. Competition Matrix of Top 5 Market Leaders
  • 20.2. SWOT Analysis for Top 5 Players
  • 20.3. Key Players Landscape for Top 10 Market Players
    • 20.3.1. GlaxoSmithKline plc
      • 20.3.1.1. Company Details
      • 20.3.1.2. Key Management Personnel
      • 20.3.1.3. Products and Services
      • 20.3.1.4. Financials (As Reported)
      • 20.3.1.5. Key Market Focus and Geographical Presence
      • 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
    • 20.3.2. Merck & Co., Inc.
    • 20.3.3. Bayer AG
    • 20.3.4. Pfizer Inc.
    • 20.3.5. Astellas Pharma Inc.
    • 20.3.6. Abbott Laboratories
    • 20.3.7. Novartis AG
    • 20.3.8. Glenmark Pharmaceuticals Limited
    • 20.3.9. Enzon Pharmaceuticals, Inc.
    • 20.3.10. Sanofi S.A.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

21. Strategic Recommendations

22. About Us and Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Antifungal Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 2. Global Antifungal Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 3. Global Antifungal Drugs Market Share (%), By Indication, 2018-2032F
  • Figure 4. Global Antifungal Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 5. Global Antifungal Drugs Market Share (%), By Medication, 2018-2032F
  • Figure 6. Global Antifungal Drugs Market Share (%), By Type, 2018-2032F
  • Figure 7. Global Antifungal Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 8. Global Antifungal Drugs Market Share (%), By Region, 2018-2032F
  • Figure 9. North America Antifungal Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 10. North America Antifungal Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 11. North America Antifungal Drugs Market Share (%), By Indication, 2018-2032F
  • Figure 12. North America Antifungal Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 13. North America Antifungal Drugs Market Share (%), By Medication, 2018-2032F
  • Figure 14. North America Antifungal Drugs Market Share (%), By Type, 2018-2032F
  • Figure 15. North America Antifungal Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 16. North America Antifungal Drugs Market Share (%), By Country, 2018-2032F
  • Figure 17. United States Antifungal Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 18. United States Antifungal Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 19. United States Antifungal Drugs Market Share (%), By Indication, 2018-2032F
  • Figure 20. United States Antifungal Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 21. United States Antifungal Drugs Market Share (%), By Medication, 2018-2032F
  • Figure 22. United States Antifungal Drugs Market Share (%), By Type, 2018-2032F
  • Figure 23. United States Antifungal Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 24. Canada Antifungal Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 25. Canada Antifungal Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 26. Canada Antifungal Drugs Market Share (%), By Indication, 2018-2032F
  • Figure 27. Canada Antifungal Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 28. Canada Antifungal Drugs Market Share (%), By Medication, 2018-2032F
  • Figure 29. Canada Antifungal Drugs Market Share (%), By Type, 2018-2032F
  • Figure 30. Canada Antifungal Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 31. Mexico Antifungal Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 32. Mexico Antifungal Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 33. Mexico Antifungal Drugs Market Share (%), By Indication, 2018-2032F
  • Figure 34. Mexico Antifungal Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 35. Mexico Antifungal Drugs Market Share (%), By Medication, 2018-2032F
  • Figure 36. Mexico Antifungal Drugs Market Share (%), By Type, 2018-2032F
  • Figure 37. Mexico Antifungal Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 38. Europe Antifungal Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 39. Europe Antifungal Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 40. Europe Antifungal Drugs Market Share (%), By Indication, 2018-2032F
  • Figure 41. Europe Antifungal Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 42. Europe Antifungal Drugs Market Share (%), By Medication, 2018-2032F
  • Figure 43. Europe Antifungal Drugs Market Share (%), By Type, 2018-2032F
  • Figure 44. Europe Antifungal Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 45. Europe Antifungal Drugs Market Share (%), By Country, 2018-2032F
  • Figure 46. Germany Antifungal Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 47. Germany Antifungal Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 48. Germany Antifungal Drugs Market Share (%), By Indication, 2018-2032F
  • Figure 49. Germany Antifungal Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 50. Germany Antifungal Drugs Market Share (%), By Medication, 2018-2032F
  • Figure 51. Germany Antifungal Drugs Market Share (%), By Type, 2018-2032F
  • Figure 52. Germany Antifungal Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 53. France Antifungal Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 54. France Antifungal Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 55. France Antifungal Drugs Market Share (%), By Indication, 2018-2032F
  • Figure 56. France Antifungal Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 57. France Antifungal Drugs Market Share (%), By Medication, 2018-2032F
  • Figure 58. France Antifungal Drugs Market Share (%), By Type, 2018-2032F
  • Figure 59. France Antifungal Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 60. Italy Antifungal Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 61. Italy Antifungal Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 62. Italy Antifungal Drugs Market Share (%), By Indication, 2018-2032F
  • Figure 63. Italy Antifungal Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 64. Italy Antifungal Drugs Market Share (%), By Medication, 2018-2032F
  • Figure 65. Italy Antifungal Drugs Market Share (%), By Type, 2018-2032F
  • Figure 66. Italy Antifungal Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 67. United Kingdom Antifungal Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 68. United Kingdom Antifungal Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 69. United Kingdom Antifungal Drugs Market Share (%), By Indication, 2018-2032F
  • Figure 70. United Kingdom Antifungal Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 71. United Kingdom Antifungal Drugs Market Share (%), By Medication, 2018-2032F
  • Figure 72. United Kingdom Antifungal Drugs Market Share (%), By Type, 2018-2032F
  • Figure 73. United Kingdom Antifungal Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 74. Russia Antifungal Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 75. Russia Antifungal Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 76. Russia Antifungal Drugs Market Share (%), By Indication, 2018-2032F
  • Figure 77. Russia Antifungal Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 78. Russia Antifungal Drugs Market Share (%), By Medication, 2018-2032F
  • Figure 79. Russia Antifungal Drugs Market Share (%), By Type, 2018-2032F
  • Figure 80.
  • Figure 81. Russia Antifungal Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 82. Netherlands Antifungal Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 83. Netherlands Antifungal Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 84. Netherlands Antifungal Drugs Market Share (%), By Indication, 2018-2032F
  • Figure 85. Netherlands Antifungal Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 86. Netherlands Antifungal Drugs Market Share (%), By Medication, 2018-2032F
  • Figure 87. Netherlands Antifungal Drugs Market Share (%), By Type, 2018-2032F
  • Figure 88. Netherlands Antifungal Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 89. Spain Antifungal Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 90. Spain Antifungal Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 91. Spain Antifungal Drugs Market Share (%), By Indication, 2018-2032F
  • Figure 92. Spain Antifungal Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 93. Spain Antifungal Drugs Market Share (%), By Medication, 2018-2032F
  • Figure 94. Spain Antifungal Drugs Market Share (%), By Type, 2018-2032F
  • Figure 95. Spain Antifungal Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 96. Turkey Antifungal Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 97. Turkey Antifungal Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 98. Turkey Antifungal Drugs Market Share (%), By Indication, 2018-2032F
  • Figure 99. Turkey Antifungal Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 100. Turkey Antifungal Drugs Market Share (%), By Medication, 2018-2032F
  • Figure 101. Turkey Antifungal Drugs Market Share (%), By Type, 2018-2032F
  • Figure 102. Turkey Antifungal Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 103. Poland Antifungal Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 104. Poland Antifungal Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 105. Poland Antifungal Drugs Market Share (%), By Indication, 2018-2032F
  • Figure 106. Poland Antifungal Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 107. Poland Antifungal Drugs Market Share (%), By Medication, 2018-2032F
  • Figure 108. Poland Antifungal Drugs Market Share (%), By Type, 2018-2032F
  • Figure 109. Poland Antifungal Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 110. South America Antifungal Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 111. South America Antifungal Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 112. South America Antifungal Drugs Market Share (%), By Indication, 2018-2032F
  • Figure 113. South America Antifungal Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 114. South America Antifungal Drugs Market Share (%), By Medication, 2018-2032F
  • Figure 115. South America Antifungal Drugs Market Share (%), By Type, 2018-2032F
  • Figure 116. South America Antifungal Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 117. South America Antifungal Drugs Market Share (%), By Country, 2018-2032F
  • Figure 118. Brazil Antifungal Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 119. Brazil Antifungal Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 120. Brazil Antifungal Drugs Market Share (%), By Indication, 2018-2032F
  • Figure 121. Brazil Antifungal Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 122. Brazil Antifungal Drugs Market Share (%), By Medication, 2018-2032F
  • Figure 123. Brazil Antifungal Drugs Market Share (%), By Type, 2018-2032F
  • Figure 124. Brazil Antifungal Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 125. Argentina Antifungal Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 126. Argentina Antifungal Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 127. Argentina Antifungal Drugs Market Share (%), By Indication, 2018-2032F
  • Figure 128. Argentina Antifungal Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 129. Argentina Antifungal Drugs Market Share (%), By Medication, 2018-2032F
  • Figure 130. Argentina Antifungal Drugs Market Share (%), By Type, 2018-2032F
  • Figure 131. Argentina Antifungal Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 132. Asia-Pacific Antifungal Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 133. Asia-Pacific Antifungal Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 134. Asia-Pacific Antifungal Drugs Market Share (%), By Indication, 2018-2032F
  • Figure 135. Asia-Pacific Antifungal Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 136. Asia-Pacific Antifungal Drugs Market Share (%), By Medication, 2018-2032F
  • Figure 137. Asia-Pacific Antifungal Drugs Market Share (%), By Type, 2018-2032F
  • Figure 138. Asia-Pacific Antifungal Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 139. Asia-Pacific Antifungal Drugs Market Share (%), By Country, 2018-2032F
  • Figure 140. India Antifungal Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 141. India Antifungal Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 142. India Antifungal Drugs Market Share (%), By Indication, 2018-2032F
  • Figure 143. India Antifungal Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 144. India Antifungal Drugs Market Share (%), By Medication, 2018-2032F
  • Figure 145. India Antifungal Drugs Market Share (%), By Type, 2018-2032F
  • Figure 146. India Antifungal Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 147. China Antifungal Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 148. China Antifungal Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 149. China Antifungal Drugs Market Share (%), By Indication, 2018-2032F
  • Figure 150. China Antifungal Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 151. China Antifungal Drugs Market Share (%), By Medication, 2018-2032F
  • Figure 152. China Antifungal Drugs Market Share (%), By Type, 2018-2032F
  • Figure 153. China Antifungal Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 154. Japan Antifungal Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 155. Japan Antifungal Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 156. Japan Antifungal Drugs Market Share (%), By Indication, 2018-2032F
  • Figure 157. Japan Antifungal Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 158. Japan Antifungal Drugs Market Share (%), By Medication, 2018-2032F
  • Figure 159. Japan Antifungal Drugs Market Share (%), By Type, 2018-2032F
  • Figure 160. Japan Antifungal Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 161. Australia Antifungal Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 162. Australia Antifungal Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 163. Australia Antifungal Drugs Market Share (%), By Indication, 2018-2032F
  • Figure 164. Australia Antifungal Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 165. Australia Antifungal Drugs Market Share (%), By Medication, 2018-2032F
  • Figure 166. Australia Antifungal Drugs Market Share (%), By Type, 2018-2032F
  • Figure 167. Australia Antifungal Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 168. Vietnam Antifungal Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 169. Vietnam Antifungal Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 170. Vietnam Antifungal Drugs Market Share (%), By Indication, 2018-2032F
  • Figure 171. Vietnam Antifungal Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 172. Vietnam Antifungal Drugs Market Share (%), By Medication, 2018-2032F
  • Figure 173. Vietnam Antifungal Drugs Market Share (%), By Type, 2018-2032F
  • Figure 174. Vietnam Antifungal Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 175. South Korea Antifungal Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 176. South Korea Antifungal Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 177. South Korea Antifungal Drugs Market Share (%), By Indication, 2018-2032F
  • Figure 178. South Korea Antifungal Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 179. South Korea Antifungal Drugs Market Share (%), By Medication, 2018-2032F
  • Figure 180. South Korea Antifungal Drugs Market Share (%), By Type, 2018-2032F
  • Figure 181. South Korea Antifungal Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 182. Indonesia Antifungal Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 183. Indonesia Antifungal Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 184. Indonesia Antifungal Drugs Market Share (%), By Indication, 2018-2032F
  • Figure 185. Indonesia Antifungal Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 186. Indonesia Antifungal Drugs Market Share (%), By Medication, 2018-2032F
  • Figure 187. Indonesia Antifungal Drugs Market Share (%), By Type, 2018-2032F
  • Figure 188. Indonesia Antifungal Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 189. Philippines Antifungal Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 190. Philippines Antifungal Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 191. Philippines Antifungal Drugs Market Share (%), By Indication, 2018-2032F
  • Figure 192. Philippines Antifungal Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 193. Philippines Antifungal Drugs Market Share (%), By Medication, 2018-2032F
  • Figure 194. Philippines Antifungal Drugs Market Share (%), By Type, 2018-2032F
  • Figure 195. Philippines Antifungal Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 196. Middle East & Africa Antifungal Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 197. Middle East & Africa Antifungal Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 198. Middle East & Africa Antifungal Drugs Market Share (%), By Indication, 2018-2032F
  • Figure 199. Middle East & Africa Antifungal Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 200. Middle East & Africa Antifungal Drugs Market Share (%), By Medication, 2018-2032F
  • Figure 201. Middle East & Africa Antifungal Drugs Market Share (%), By Type, 2018-2032F
  • Figure 202. Middle East & Africa Antifungal Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 203. Middle East & Africa Antifungal Drugs Market Share (%), By Country, 2018-2032F
  • Figure 204. Saudi Arabia Antifungal Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 205. Saudi Arabia Antifungal Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 206. Saudi Arabia Antifungal Drugs Market Share (%), By Indication, 2018-2032F
  • Figure 207. Saudi Arabia Antifungal Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 208. Saudi Arabia Antifungal Drugs Market Share (%), By Medication, 2018-2032F
  • Figure 209. Saudi Arabia Antifungal Drugs Market Share (%), By Type, 2018-2032F
  • Figure 210. Saudi Arabia Antifungal Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 211. UAE Antifungal Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 212. UAE Antifungal Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 213. UAE Antifungal Drugs Market Share (%), By Indication, 2018-2032F
  • Figure 214. UAE Antifungal Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 215. UAE Antifungal Drugs Market Share (%), By Medication, 2018-2032F
  • Figure 216. UAE Antifungal Drugs Market Share (%), By Type, 2018-2032F
  • Figure 217. UAE Antifungal Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 218. South Africa Antifungal Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 219. South Africa Antifungal Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 220. South Africa Antifungal Drugs Market Share (%), By Indication, 2018-2032F
  • Figure 221. South Africa Antifungal Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 222. South Africa Antifungal Drugs Market Share (%), By Medication, 2018-2032F
  • Figure 223. South Africa Antifungal Drugs Market Share (%), By Type, 2018-2032F
  • Figure 224. South Africa Antifungal Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 225. By Drug Class Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 226. By Indication Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 227. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 228. By Medication Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 229. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 230. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 231. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024